Not Yet Recruiting PHASE1/PHASE2 NCT07454187
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
SG2918
Updated 1 time since 2026 Last updated: Mar 3, 2026 Started: Mar 14, 2026 Primary completion: Sep 30, 2027 Completion: Dec 31, 2028
This PHASE1/PHASE2 trial investigates Relapsed/Refractory Multiple Myeloma and is currently actively recruiting participants. Hangzhou Sumgen Biotech Co., Ltd. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Hangzhou Sumgen Biotech Co., Ltd.
Data source: Hangzhou Sumgen Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Hangzhou, China
- • Suzhou, China
- • Xi’an, China
- • Zhengzhou, China